To examine the safety and cardiovascular (CV) effects of saxagliptin in the predefined elderly ( ‡65 years) and very elderly ( ‡75 years) subpopulations of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial.
randomized controlled trials (RCTs) (3, 4) often as a result of study entry criteria, including 1) setting arbitrary caps on participant age and 2) discouraging or disallowing participants with confounding comorbidities, frailty, or polypharmacy (common in the elderly). The justification for these criteria is a concern that including such subjects may complicate study interpretation (5) . The resulting paucity of relevant data has culminated in a lack of definitive guidance on how to optimally manage glycemia in older patients with type 2 diabetes. Although many have begun to formally document recommendations for best care for the geriatric population with type 2 diabetes, these recommendations often are based on inadequate evidence (5) (6) (7) (8) . Given the increased cardiovascular (CV) risk in people with type 2 diabetes (9,10), current guidelines highlight the importance of a comprehensive, multifactorial approach to CV risk reduction, particularly among older individuals whose CV risk increases with age (5) (6) (7) (8) .
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) is a recently completed CV outcome trial designed in accordance with the 2008 U.S. Food and Drug Administration (FDA) guidance for new antihyperglycemic agents (11) . The study met its primary objective of demonstrating CV safety of the competitive dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin in a large group of individuals with type 2 diabetes and either established CV disease or multiple CV risk factors, although superiority was not shown (12) (13) (14) . Unlike many earlier studies, SAVOR-TIMI 53 had minimal exclusion criteria and did not exclude participation due to advanced age (individuals up to 99 years were randomized in the study). Accordingly, the large number of older participants in SAVOR-TIMI 53 (8,561 and 2,330 of the 16,492 participants were elderly [$65 years] and very elderly [$75 years], respectively) provided a unique opportunity to assess the safety and efficacy of saxagliptin in this important predefined population.
RESEARCH DESIGN AND METHODS
SAVOR-TIMI 53 was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 788 sites in 26 countries spanning six continents (12) (13) (14) . The study was performed according to the standards and principles of the Declaration of Helsinki. Ethics approval was site specific and always obtained before commencement at each study center. All participants provided written informed consent.
Inclusion and Exclusion Criteria
Study entry criteria have been described previously and were explicitly established to ensure that the final cohort closely reflected the real-life type 2 diabetes population (12) (13) (14) . Briefly, participants had to have a documented type 2 diabetes diagnosis, a glycated hemoglobin (HbA 1c ) level $6.5% (47.5 mmol/mol) and #12.0% (107.7 mmol/mol) at the last measurement during the 6 months before study initiation, and a history of either established CV disease or multiple risk factors (MRFs) for vascular disease (capped at 25% of the cohort size). The established CV disease criteria were $40 years of age with a documented atherosclerosis-associated event involving the coronary, cerebrovascular, or peripheral vascular system. The prerequisite MRF criteria were $55 and $60 years of age for men and women, respectively, with at least one of the following CV risk factors: dyslipidemia, hypertension, or active smoking. There was no upper limit on age at entry. Individuals who had been or were on current or previous (within 6 months) incretin-based therapy, were undergoing long-term dialysis, had a renal transplant, or had a serum creatinine level .6.0 mg/dL were excluded. ). Pharmacotherapy for type 2 diabetes and CV disease management (i.e., addition, discontinuation, dose titration) was left entirely to the discretion of the attending physician. The use of other DPP-4 inhibitors and GLP-1 receptor agonists was not permitted.
End Points and Assessments
The primary efficacy outcome was a composite of CV mortality, nonfatal myocardial infarction (MI), or nonfatal ischemic stroke. The composite secondary end point included the primary composite end point plus hospitalization for heart failure, coronary revascularization, or unstable angina. All components of the primary composite and secondary efficacy end points were adjudicated by a central, blinded, and independent events committee. All hypoglycemic episodes were collected prospectively through patient diaries that were reviewed at each visit. Hypoglycemic episodes were classified as major if they necessitated a third party to actively intervene and minor if the patient had symptoms but recovered without assistance within 30 min of ingesting carbohydrates or documented blood glucose levels ,54 mg/dL regardless of symptoms. Hypoglycemic events that required hospitalization were classified separately as hypoglycemic serious adverse events (AEs).
Statistical Analyses
Subgroup analyses by age were preplanned before unblinding this trial, and the primary hypothesis was to examine the degree of consistency of the overall treatment effect in the age groups. Thus, homogeneity of treatment effects was assessed using a Cox proportional hazards model (time to event) stratified by age groups, with treatment as the only covariate in the model and additional stratification by renal function category and baseline CV risk group. Comparisons between age groups for the demographic and baseline data and between treatments for treatment-emergent AEs for each age category were analyzed with either the x 2 or t test. Cumulative incidence is reported using Kaplan-Meier event rate at the 2-year time point. Statistical significance was considered at an unadjusted a of 0.05. Women comprised approximately onethird of the overall study population. Of note, however, nearly 40% of the very elderly participants were women. Elderly and very elderly participants had a lower mean weight than their younger counterparts (P = 0.0001); the percentage of individuals with a BMI .30 kg/m 2 was also lower in the elderly (P = 0.0001) and very elderly (P = 0.0001) groups. Although the mean duration of type 2 diabetes was longer in elderly individuals, the mean baseline fasting plasma glucose (FPG) level was higher among those ,65 years old (P = 0.0001). Individuals #65 years old were also less likely (P = 0.0001) to have a baseline HbA 1c ,8.0% (63.9 mmol/mol). Similarly, mean FPG levels (P = 0.0001) and percentage with HbA 1c .8.0% (63.9 mmol/mol) (P = 0.0001) at baseline were greater in the ,75 years age group versus very elderly participants. Eighty percent of the participants had hypertension, and 70% had dyslipidemia. Elderly participants were less likely to be current smokers. Renal insufficiency (eGFR #50 mL/min/1.73 m 2 ) was documented more frequently among the elderly and very elderly participants (P = 0.0001). Use of antihyperglycemic and CV drugs was common in all groups. Approximately 40% of the entire study population was on insulin, and this distribution remained consistent regardless of whether the group was age stratified at the 65-or 75-year mark. At baseline, ;70% of those ,75 years old were on metformin, whereas this was true for only 57% of the very elderly participants (P = 0.000).
RESULTS

Of
Mean follow-up duration was similar across age groups ( Table 2 ). The hazard ratio (HR) for the primary end point between saxagliptin and placebo was 0.92 (95% CI 0.79, 1.06) for the elderly participants vs. 1.15 (95% CI 0.96, 1.37) for those ,65 years old (P = 0.06) and 0.95 (95% CI 0.75, 1.22) for the very elderly participants vs. 1.01 (95% CI 0.89, 1.15) for those ,75 years old (P = 0.67). The HR for the secondary composite outcome was well balanced and did not reveal any treatment-by-age interaction (Table  2) . Event rates for MIs, CV mortality, and non-CV mortality were similar for placebo versus saxagliptin whether the study population was examined in its entirety or by age stratification (Table 2) . Although the HR for overall all-cause mortality was balanced, the data suggest a higher risk for the ,65-year-old subcohort of the saxagliptin arm (Table 2) . Similarly, unstable angina-associated hospitalization was modestly greater among participants in the saxagliptin arm who were ,65 years old ( Table 2) . Risk of hospitalization as a consequence of heart failure was a component of the overall balanced secondary end point, which was increased in the saxagliptin-treated participants in the overall SAVOR-TIMI 53 cohort. The analysis indicates that although the incidence of hospitalization for heart failure in all four age groups was numerically higher in the saxagliptin versus placebo group, the risk of heart failureassociated hospitalization did not demonstrate any treatment-by-age interaction (P = 0.76 for the elderly Fig. 1 . Saxagliptin and placebo produced modest changes in body weight (,1% from baseline), and similar to the overall study population, the elderly and very elderly participants showed less deteriorations and greater improvements in their albumin-tocreatinine ratio with saxagliptin versus placebo (data not shown).
There were no differences detected for AE-associated discontinuations when the cohort was divided into the ,65 vs. $65 year and ,75 vs. $75 year groups, although serious AEassociated discontinuations were more common among the elderly participants treated with placebo (vs. saxagliptin) ( Table 3 ). The incidence of overall AEs and serious AEs for saxagliptin versus placebo was comparable between age-stratified groups. The imbalance for treatmentrelated AEs observed in the very elderly participants treated with saxagliptin versus placebo was also noted in the overall population. Incidence of hypoglycemic occurrences, mostly minor in nature, was greater in the saxagliptin arm. The risk for pancreatitis was low and similar between saxagliptin-and placebo-treated groups in all age strata (Table 3 ). There was no difference in the incidence of cancer, including pancreatic cancer, between the two study arms, but participants ,75 years randomized to saxagliptin reported the occurrence of significantly less cancer of all types than the corresponding placebo arm. In the very elderly group, more patients on saxagliptin versus placebo reported cancer, but this difference was not statistically significant (Table 3) .
CONCLUSIONS
These data demonstrate that in elderly and very elderly individuals with type 2 diabetes, similar to the entire SAVOR-TIMI 53 cohort, the use of the DPP-4 inhibitor saxagliptin was associated with no increased risk of ischemic events, but without superiority relative to placebo, as well as with enhanced glycemic control with no weight gain. The observed increased risk of hospitalization for heart failure and hypoglycemic episodes with saxagliptin was similar, regardless of age.
The number of type 2 diabetes cases globally continues to soar, with the aging population contributing to this growth (1). Nonetheless, clinical trial evidence in older populations with diabetes is relatively limited. A recent descriptive analysis reported that of the 2,484 interventional diabetes-relevant trials registered at ClinicalTrials.gov, 31% excluded individuals .65 years, most excluded those .75 years, and 0.6% included only elderly participants (4). These findings were echoed in a review of the World Health Organization Clinical Trials Registry Platform where of the 440 studies examining type 2 diabetes therapies, nearly 66% excluded individuals based on an arbitrary upper age limit (3). This worrisome evidence gap has led to the question of whether it is sound clinical practice to extrapolate the findings derived from type 2 diabetes (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . Two meta-analyses suggested that the DPP-4 inhibitors are associated with reduced CV risk (23, 24) . Importantly, however, these data were obtained predominantly from relatively small and/or short-term investigations (18, 19, 30) , systematic reviews (21, 28, 29) , and pooled analyses (20, 22, (25) (26) (27) 31, 32) in by-and-large younger and healthier study participants with very limited, and generally unadjudicated, CV safety information.
The SAVOR-TIMI 53 trial was a large, multinational RCT designed to demonstrate the safety (overall and CV) and efficacy of saxagliptin beyond glucose lowering. Per the 2008 FDA guidance (11), the SAVOR-TIMI 53 cohort included a robust number of persons .40 years old and into their 90s with a broad duration of type 2 diabetes, with renal function ranging from normal to poor, and on a spectrum of antihyperglycemic and CV medications. It is notable that baseline and in-study glycemic control were better in the elderly group despite little difference in insulin usage across the age-stratified groups. Whether these observations resulted from differential management practices is beyond the scope of this article.
The present data represent the first from a large-scale multinational study population demonstrating that saxagliptin, at a dose that improves glycemic control in older individuals with type 2 diabetes, is not accompanied by an increase in CV ischemic events among very elderly patients. As previously reported (13), hospitalization for heart failure showed a nominal statistically significant excess in the overall saxagliptin population, but there was no heterogeneity as a function of age. Weight gain, an unwelcomed side effect of several traditional antihyperglycemic agents, did not occur with saxagliptin therapy. Hypoglycemia was only slightly higher in those randomized to saxagliptin, although this excess has been shown to have occurred in those on background sulphonylureas and with a baseline HbA 1c ,7.0% (53.0 mmol/mol) (33) . This finding is important because age is an independent risk factor for hypoglycemia (10, 34, 35) . Furthermore, age-related comorbidities and severe oscillations in glucose levels in elderly patients due to poor or noncompliant management may increase the risk for hypoglycemia and may contribute to cognitive disorders and physical debilitation (35, 36) . Importantly, the results from this work indicate that the overall safety and efficacy profiles of saxagliptin at the doses studied are age independent. In addition, the present findings demonstrating that saxagliptin produces better glycemic control and is associated with AE incidence that is no worse in older versus younger individuals extend those previously reported (20, 22) . This study provides evidence regarding the safety and efficacy of saxagliptin as both monotherapy and add-on therapy to a wide variety of antihyperglycemic agents, including insulin, in individuals of all ages, including elderly and very elderly.
Linagliptin has been reported in subjects $70 years to also have similar safety, tolerability, and hypoglycemic profiles (18) . However, the short 24-week follow-up meant that it was not possible to collect more clinically relevant long-term data, although these data will likely be forthcoming from the ongoing CAROLINA (Cardiovascular (26) and very elderly (n = 301) (27) individuals treated with vildagliptin experienced comparable benefits with similar or fewer AEs than younger individuals, regardless of renal function being either normal or mildly insufficient. Recently, a retrospective analysis reported greater HbA 1c ,7.0% (53.0 mmol/mol) achievement, better compliance, and lower incidences of hypoglycemia with vildagliptin (vs. sulfonylurea/glitazone) add-on to metformin in elderly individuals (38) . Impending reports from TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) will undoubtedly shed additional insight on the use of this class of drugs in elderly patients with diabetes (39) .
Although the numerical change in HbA 1c and FPG levels in SAVOR-TIMI 53 was relatively modest, this efficacy was observed despite the study being designed to minimize any glycemic differences between the two arms by encouraging the blinded study investigators to treat glycemia per local guidelines. The fact that the HbA 1c levels in both arms remained above target is not surprising given the consistent demonstration that guidelines-recommended HbA 1c goals are rarely achieved in practice (40) (41) (42) . Furthermore, newer guidelines now endorse personalizing diabetes management for the elderly patient in whom the general HbA 1c goal of ,7.0% (53 mmol/mol) may or may not be appropriate (5) (6) (7) (8) .
This study has several strengths and limitations. The study entry conditions and CV end points were in line with those recently published by the FDA (11). Specifically, this was a rigorously conducted large-scale, multinational study. Older individuals (elderly and, importantly, very elderly patients) at various stages along the type 2 diabetes continuum, with varying degrees of renal insufficiency, and on multiple combinations of antihyperglycemic and CV medications comprised a significant percentage of the cohort. The median follow-up of 2.1 years facilitated valuable assessments of CV safety but was probably not sufficiently long to assess CV efficacy. Internal validity was further ensured by encouraging participating physicians to establish HbA 1c goals and manage glycemia per local guidelines. Limitations include absence of cognitive function and frailty examinations at entry and as outcome measures as well as only having a 40% female representation while the majority of elderly individuals with type 2 diabetes are women. Furthermore, because all participants had to possess sufficient cognitive ability to provide informed consent to participate in the study and had to be sufficiently functional to attend regular study visits, this limited the number of frail and cognitively impaired elderly participants.
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